tbuckley/cabot-search huggingface dataset:
NIMG-15. ADVANTAGE OF HIGH B-VALUE DIFFUSION-WEIGHTED IMAGING FOR DIFFERENTIATION OF HEMANGIOBLASTOMA FROM METASTATIC TUMORS IN POSTERIOR FOSSA
Authors: Shumpei Onishi, Fumiyuki Yamasaki, Takeshi Takayasu, Ryo Nosaka, Manish Kolakshyapati, Taiichi Saito, Kazuhiko Sugiyama, Kaoru Kurisu
Journal: Neuro-Oncology (2016)

It is sometimes difficult to make differential image diagnosis between brain metastases and hemangioblastoma originating in posterior fossa. The most common type of posterior fossa tumor in adult is brain metastases, followed by hemangioblastoma. As it is quite different to manage the patients with hemangioblastoma from those of brain metastases, preoperative differentiation plays a crucial role. We assessed whether high b-value diffusion weighted image (DWI) at b-4000 could differentiate these tumors. We acquired DWI at 3T magnetic resonance imaging (MRI) with b = 1000 and b = 4000 s/mm2 in histologically confirmed 12 patients of hemangioblastoma and 16 patients of brain metastases. Apparent diffusion coefficient (ADC) values were measured by manually placing regions of interest (ROIs) on ADC maps at the site of enhanced tumor confirmed on contrast-enhanced T1- weighed image. ADC was expressed as the minimum (ADCMIN), mean (ADCMEAN), and maximum (ADCMAX) values. All the ADC values of hemangioblastoma were statistically higher than that of metastatic tumor in both b-1000 and b-4000 (p<0.0001 in ADCMIN, ADCMEAN and ADCMAX; Mann - Whitney U-test). With the cut-off value at 0.6 x 10-3mm2/sec, positive predictive value of ADCMIN at b-4000 was higher than that of ADCMINat b-1000 (100% vs 89.3%, logistic analysis) to differentiate hemangioblastoma from brain metastases. High b-value DWI reflects diffusion more accurately than regular b-value. Our results showed that ADC value based on high b value (b-4000) DWI at 3T MRI is clinically useful for differentiation hemangioblastoma from brain metastases.
Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients
Authors: Antonio Palumbo, Sara Bringhen, Davide Rossi, Maide Cavalli, Roberto Ria, Silvia Gentilini, Francesca Patriarca, Chiara Nozzoli, Anna Levi, Tommasina Guglielmelli, Giulia Benevolo, Donatella Vincelli, Luca Baldini, Fortunato Morabito, Mariella Grasso, Roberto Marasca, Manuela Rizzo, Chiara Pautasso, Antonietta Pia Falcone, Daniela Gottardi, Vittorio Montefusco, Caterina Musolino, Clotilde Cangialosi, Giovanna Mansueto, Anna Marina Liberati, Valeria Magarotto, Paola Omedè, Pellegrino Musto, Maria Teresa Petrucci, Mario Boccadoro
Journal: Blood (2012)
An Essential Role for STAT1 Signaling in Regulation of Donor CD4+ T Cell Dependent Acute Graft Versus Host Disease (GVHD) Following Allogeneic Bone Marrow Transplantation (BMT).
Authors: Huihui Ma, Caisheng Lu, Judith Ziegler, Suzanne Lentzsch, Markus Y. Mapara
Journal: Blood (2009)
Abstract A30: Novel non-COX inhibitory sulindac derivative with PDE10 inhibitory activity reduces incidence and multiplicity of colorectal adenomas in the APC+/min-FCCC mouse model
Authors: Kevin J. Lee, Xi Chen, Jacob Valiyaveettil, Ashley S. Lindsey, Joel Andrews, Veronica Ramirez-Alcantara, Adam B. Keeton, Gary A. Piazza, Margie L. Clapper, Wen-Chi L. Chang
Journal: Cancer Research (2017)

Abstract Sulindac has been reported to reduce the number and size of precancerous colonic adenomas in patients with familial adenomatous polyposis (FAP), but is not recommended for long-term use as a cancer chemopreventive drug because of potentially fatal toxicities associated with cyclooxygenase (COX) inhibition. We report here a novel sulindac derivative, ADT-061, that lacks COX-1 and COX-2 inhibitory activity, yet potently and selectively inhibits colon tumor cells with IC50 values of 0.3-0.5 μM with no significant effect on the growth of normal colonocytes. By comparison, sulindac sulfide inhibits colon tumor cell growth with IC50 values of 40-60 μM, and has only modest tumor cell selectivity. ADT-061 inhibits phosphodiesterase 10A (PDE10), which increases intracellular cGMP levels, thus activates protein kinase G, suppresses nuclear levels of β-catenin, and induces cell cycle arrest and apoptosis, all within the same concentration range that inhibits tumor cell growth. ADT-061was evaluated for chemopreventive activity in the APC+/min-FCCC mouse model of colon cancer, which harbors colorectal adenomas that express PDE10. Colonoscopy exams were initially performed on all mice to ensure the absence of colorectal adenomas prior to treatment. At 7-8 weeks of age, male mice were treated with ADT-061 (1000ppm and 1500ppm) in the diet for 14 weeks. ADT-061 reduced the incidence of colorectal adenomas from 95.8% in the control group to 73.9% in the 1000ppm group (p=0.048), and 59.1% (p=0.004) in the 1500ppm group. Control untreated mice had an average of 2.98 colorectal adenomas per mouse, while mice treated with 1000ppm and 1500ppm ADT-061 had an average of 2.04 (p=0.102) and 1.91 (p=0.039) adenomas per mouse, respectively. These observations suggest that ADT-061, or analogs thereof, merit further drug development efforts for colorectal cancer chemoprevention. Citation Format: Kevin J. Lee, Xi Chen, Jacob Valiyaveettil, Ashley S. Lindsey, Joel Andrews, Veronica Ramirez-Alcantara, Adam B. Keeton, Gary A. Piazza, Margie L. Clapper, Wen-Chi L. Chang. Novel non-COX inhibitory sulindac derivative with PDE10 inhibitory activity reduces incidence and multiplicity of colorectal adenomas in the APC+/min-FCCC mouse model. [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes; 2016 Sep 17-20; Tampa, FL. Philadelphia (PA): AACR; Cancer Res 2017;77(3 Suppl):Abstract nr A30.
CCR1 Inhibition Targets Osteoclast-Myeloma Adhesion and Exerts in Vivo Anti-Osteoclast Activity
Authors: Soni a Vallet, Nileshwari Vaghela, Mariateresa Fulciniti, Petter Veiby, Teru Hideshima, Samantha Pozzi, Loredana Santo, Siddhartha Mukherjee, Diana Cirstea, David T. Scadden, Kenneth C. Anderson, Noopur Raje
Journal: Blood (2008)
Assessment of the relationship between three cancer survivor well-being tools.
Authors: Paula Marchionda, Mary Jo Deprey, Stuart Chamovitz, Marty Jacobson, Kathleen Hall
Journal: Journal of Clinical Oncology (2016)

74 Background: In 1999, the National Comprehensive Cancer Network issued guidelines for improving well-being of cancer survivors. Three tools, the Eastern Cooperative Oncology Group Performance Status (ECOGPS), the National Comprehensive Cancer Network Distress Thermometer (NCCNDT), and the Subjective Happiness Scale (SHS), are currently being used in a rural oncology survivorship clinic to assess patients’ well-being. The question arose whether all three tools are necessary for adequate patient assessment. Methods: Charts were reviewed on patients seen in a cancer survivorship clinic between January 1, 2015 and January 31, 2016. Well-being measures included the ECOGPS, the NCCNDT, and the SHS, all of which have been validated in prior studies. Patient demographics and well-being measures were captured in a database. Patient identifiers were removed to protect privacy. Data was stratified by age, gender, type and stage of cancer, and treatment type. ECOGPS, NCCNDT, and SHS scores were analyzed using Spearman rho to determine the relationships, if any, among the scores. A strong relationship was present if the correlation coefficient was &gt; ± 0.7. A moderate relationship was present if the correlation coefficient was ± 0.4 to ± 0.7. Results: An analysis of all patient visits (n = 158) showed no strong or moderate correlations between performance and happiness (r s = -0.207), performance and distress (r s = 0.393), or distress and happiness (r s = -0.383). However, in subgroup analyses, a strong correlation was seen between happiness and performance for ages18-39 (r s = 0.830) and for those 6-12 months post-treatment (r s = -0.714). A strong correlation was also seen between distress and happiness for thoracic (r s = -0.801) and head and neck (r s = -0.847) cancer types, as well as those 1-3 years (r s = -0.718) and 3-5 years (r s = -.0754) post-treatment. A positive correlation was seen between performance and happiness for men (r s = 0.341), whereas females saw a negative correlation (r s = -0.349). Conclusions: Results indicate that these tools capture different aspects of patients’ well-being. Continued use of all three is recommended. Results obtained from stratified groups may be used for future studies.
Comment on Epidermal Hyperplasia and Tumor Promotion
Authors: J. V. Frei
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Comment on Epidermal Hyperplasia and Tumor Promotion Get access J. V. Frei, M.D. J. V. Frei, M.D. Professor of Pathology The University of Western Ontario Health Sciences Center, London, Ontario, Canada N6A 5B7 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 2, August 1977, Pages 299–300, https://doi.org/10.1093/jnci/59.2.299 Published: 01 August 1977
A Prognostic Scoring System for Patients ≤ 60 Years of Age with Acute Lymphocytic Leukemia in First Relapse.
Authors: Anjali Advani, Tao Jin, Brian J. Bolwell, Edward A. Copelan, Mikkael A Sekeres, Ronald Sobecks, Shawnda Sungren, Melissa Yurch, Matt Kalaycio
Journal: Blood (2008)
A Novel STAT1 Mutation in a Child with Pulmonary Mycobacterium avium Complex (MAC) Infection and Multifocal Lytic Bone Lesions
Authors: Huyen-Tran Nguyen, Elizabeth P. Sampaio, Lindsey B. Rosen, Steven M. Holland, Zeynep Yesim Kucuk
Journal: Journal of Allergy and Clinical Immunology (2017)
Annals Story Slam - Leonard
Authors: James D. Plumb
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 February 2017Annals On Being a Doctor Story Slam - LeonardFREEJames D. Plumb, MD, MPHJames D. Plumb, MD, MPHFrom Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0022 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Leonard "Leonard," by James Plumb, MD (Duration 5:13)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Current Author Address: James D. Plumb, MD, MPH, Thomas Jefferson University Hospital, Philadelphia, PA; e-mail, james.[email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 February 2017Volume 166, Issue 3Page: SS1 ePublished: 7 February 2017 Issue Published: 7 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Isolated BAL Neutrophilia and Unimodal Airway Epithelial IL-13 Inducible Gene Signatures Characterize Children with Treatment-Resistant Asthma
Authors: Larry Borish, Thomas J. Braciale, Debbie-Ann Shirley, John W. Steinke, Sandford Williams, Karlyn Pollack, Brian J. Capaldo, W. Gerald Teague
Journal: Journal of Allergy and Clinical Immunology (2017)
<sup>11</sup>C-choline PET scanning is more accurate than biopsy in assessment of localized prostate cancer planned for radical prostatectomy.
Authors: Ian D. Davis, Sze Ting Lee, Lekshmy Shanker, David Clouston, Damien M Bolton, David Angus, David Webb, Nathan Lawrentschuk, Dixon Teck Sing Woon, Stephen Esler, Daryl Lim Joon, Joe Chang, Richard O'Sullivan, Kunthi Pathmaraj, Henri Tochon-Danguy, Graeme Joseph O'Keefe, Andrew Mark Scott
Journal: Journal of Clinical Oncology (2012)

182 Background: A decision to treat prostate cancer (PC) with radical prostatectomy (RP) with curative intent requires confidence that the PC is confined to the prostate. PC outcomes will improve with better selection of surgical candidates. Current imaging modalities include CT and MRI but have limited accuracy. We assessed 18 F-FDG (FDG) and 11 C-choline (CHOL) PET in men planned for RP to determine the accuracy of PET, effects of PET on decision making by surgeons, and correlation with PSA. Methods: Written informed consent was obtained from eligible participants (pts) planned for RP. All men underwent TRUS-guided prostatic biopsies, CT and MRI scans, PSA and standard tests of organ function. The urologist then documented the treatment plan based on these results. Pts then underwent FDG and CHOL PET and the urologist then determined whether this information altered the treatment plan. After surgery the RP specimen was reconstructed, examined histologically and correlated with TRUS and imaging results on a sextant-based analysis (apex/mid/base on both sides). Results: 30 pts entered and completed the trial. Outcomes are shown in the table. Neither PET modality significantly affected decisions about surgery. Preoperative PSA did not correlate with degree of involvement. FDG PET was unhelpful. Conclusions: CHOL PET was the most sensitive and most accurate modality with highest congruity with pathology and had excellent positive predictive value, but was least specific. CHOL PET was superior to both TRUS biopsy and MRI. Supported by grant 487916 through Cancer Australia, Prostate Cancer Foundation Australia, Australian Government Department of Health and Aging. [Table: see text]
Study of Pneumocystis Pneumonia of Trimethoprim/Sulfamethoxazole in NHL patients receiving R-CHOP regimen
Authors: Yuta Ishiyama, Tatsu Shimoyama, Yuki Sasaki, Miho Tamura, Takeshi Sawada, Yusuke Kanemasa, Yasushi Omuro, Yoshiharu Maeda
Journal: Annals of Oncology (2016)
Characteristics and Survival of 29 Patients with Sezary Syndrome.
Authors: Francesca Sampogna, Marina Frontani, Giannandrea Baliva, Damiano Abeni, Giuseppe A. Lombardo, Alessandro Monopoli, Claudio Barbieri, Roberto Benucci, Giuseppe Marrazza, Gabriele Alvetreti, Biagio Didona, Enrico Scala, Giandomenico Russo
Journal: Blood (2005)
Oncologists' perception of residual cancer recurrence risk and recommended follow-up care.
Authors: Arnab Basu, Kenneth David Miller
Journal: Journal of Clinical Oncology (2016)

151 Background: Many medical oncologists avoid using the word "cure" even at 20 years post-diagnosis. Little data has been reported on oncologists' perceptions of patients’ residual risk of recurrence and their recommendations for follow-up care. Methods: E-mail requests were sent to oncologists to review four brief case scenarios and to indicate their perception of the patients’ residual risk of recurrence (Essentially Zero, 1-10%, 11-25%, 26-50%, 51-75%, 76-100%) and their recommended follow-up care. We also conducted a literature review to estimate actual recurrence risks for these stated scenarios. Results: 130 medical oncologists responded. The percentage who perceived a zero or essentially zero risk of recurrence steadily increased at the 5,10, 15, and 20+ year post-diagnosis time points in patients with Stage II triple negative breast, Stage II colon, Stage II lung, and Diffuse Large B-cell Lymphoma. Follow-up for 20+ years was recommended by 43%, 27%, 32%, and 38% of respondents respectively. Among respondents who recommended this long-term follow-up 37%, 63%, 57%, and 58% perceived no residual risk of recurrence after 20 years. There was no statistically significant relationship between recommending follow-up at &gt; 20 years and the perception of the patient having a non-zero risk of recurrence. Even at twenty years post-diagnosis a &gt; 10% risk of recurrence was expected by 14%, 8%, 10%, and 11% of respondents.However,a literature review indicated recurrence risks of &lt; 5% after 10 years of disease free survival for patients with each described scenario. At 10 and 15 years, participants indicated the two most common reasons for follow up were screening for late and long-term effects followed by screening for new cancer Conclusions: The risk of cancer recurrence is typically greatest in the initial years after diagnosis and then decreases, especially after 10 years. In this study, many medical oncologists still perceived a &gt; 10% residual risk of recurrence at 10, 15, and 20 years post-diagnosis and recommended follow-up visits.
心筋梗塞・レジオネラ肺炎による心不全・呼吸不全にPCI,IABP,HFO,NO吸入療法等の治療が奏功した1例
Authors: 竹内崇博, 相澤万象, 笠井宏樹, 富田威, 内川慎一郎, 熊崎節央, 筒井洋, 矢崎善一, 木下脩, 池田宇一, 今村浩, 永春幸子, 関口幸男, 岡元和文
Journal: Circulation (2007)
TMIC-18. ROLE OF MICROGLIA IN THE EARLY STEPS OF THE BRAIN METASTATIC CASCADE
Authors: Anna Berghoff, Manuel Feinauer, Gergely Solecki, Julia Grosch, Matthias Osswald, Brunilde Gil, Dorothee Wilhelm, Ursula Raiky, Johannes Hainfellner, Patricia Steeg, Peter Birner, Matthias Preusser, Wolfgang Wick, Frank Winkler
Journal: Neuro-Oncology (2016)

Gliomas are one of the cancers most at risk of causing life-threatening venous thromboemboli (VTE).Previously, we discovered that gliomas with mutations in isocitrate dehydrogenase (IDH1mut) are much less likely to contain intratumoral microthrombi, and are much less likely to cause peripheral VTE, compared to IDH1 wild-type (IDH1wt) gliomas.We also found that IDH1mut gliomas have methylation-associated suppression of Tissue Factor (TF), a key initiator of thrombosis.Furthermore, prior studies have shown that TF directly increases the malignancy of many cancers through multiple transmembrane signaling pathways.In the current study, we further explored the significance of TF in IDH1wt and IDH1mut gliomas.Three IDH1wt patient derived cell lines (GBM6, GBM12, GBM43) had high levels of TF protein and TF procoagulant activity in vitro, whereas 3 lines of patient-derived endogenous IDH1mut glioma cells (TB09, GBM164, BT142) had very low TF expression and activity.Exogenous treatment with the product of IDH1mut enzyme, D-2-hydroxyglutarate, suppressed the procoagulant activity of TF by up to 28% in IDH1wt cells.Likewise, induced expression of IDH1mut suppressed TF activity by 36% in IDH1wt cells.Thus far, in an ongoing prospective assessment of TF activity in the systemic circulation of glioma patients, 7/32 (22%) IDH1wt patients have had highly active circulating TF (defined as >2.0 pg/mL factor Xa generation), whereas 0/15 (0%) IDH1mut gliomas did-a pattern already trending toward significance (P=0.08).Among the 3 IDH1wt glioma cell lines, there was a direct correlation between TF expression and transwell migration, and TF knockdown with shRNA decreased migration by 93% (P=0.024).TF knockdown also reduced the average growth rate of orthotopic IDH1wt patient-derived glioma xenografts by 92%, as measured with bioluminescence imaging (P=0.03).These findings further indicate that suppression of TF expression and activity may be a critical component of the less thrombogenic, and less malignant, IDH1mut phenotype.
A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study
Authors: A.H. Bryce, J.J. Alumkal, A. Armstrong, C.S. Higano, P. Iversen, C.N. Sternberg, D.E. Rathkopf, Y. Loriot, J. de Bono, B. Tombal, S. Abhyankar, P. Lin, A. Krivoshik, D. Phung, T.M. Beer
Journal: Annals of Oncology (2016)
Clinical Results in Heavily Pre-Treated, Drug Refractory Hematologic Malignancies Using Chemotherapy and Targeted Agents Selected By Ex Vivo Analysis of Programmed Cell Death (EVA/PCD)
Authors: Vinicius Renan Pinto Mattos, Nelson Hamerschlak, Isabel Nagle Reis, Dirceu Hamilton Cordeiro Campelo, Michelle Petrolli Silveira, Flavia Munhoz Ferreira, Juliano Cordova Vargas, Paulo Vidal Campregher, Fabio P.S. Santos, Fabio R. Kerbauy, Joao C. C. Guerra, Claudio Galvão Castro Júnior, Steven S. Evans, Robert Nagourney
Journal: Blood (2015)
Physiological Non-Responsiveness and Absence of Activation Induced Cell Death of T Cells Rapidly Re-Expressing Retrovirally Introduced TCRs after T Cell Activation.
Authors: Marleen van Loenen, Renate Hagedoorn, Esther van Egmond, Roelof Willemze, J.H. Frederik Falkenburg, Mirjam Heemskerk
Journal: Blood (2007)
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation
Authors: Kenichi Suda, Isao Murakami, Hui Yu, Jihye Kim, Kim Ellison, Christopher J. Rivard, Tetsuya Mitsudomi, Fred R. Hirsch
Journal: Journal of Thoracic Oncology (2017)
The associations between participation in certain sports and lower mortality are not explained by affluence and other socioeconomic factors
Authors: Emmanuel Stamatakis, Paul Kelly, Sylvia Titze, Zeljko Pedisic, Adrian Bauman, Charlie Foster, Mark Hamer, Melvyn Hillsdon, Pekka Oja
Journal: British Journal of Sports Medicine (2017)

Our recent paper1 examined the type-specific associations between sports and all cause and cardiovascular disease (CVD) mortality. Among the wide media attention,2 CNN reported our finding as ‘Swimming, aerobics, racquet sports slash risk of death’3 and those three sports that showed the largest reductions in mortality risk (as indicated by the HR value).4 Running and football (soccer)/rugby5 showed limited beneficial associations with mortality. While it was beyond the capacity and scope of our research to undertake comparisons between different sports and explain why these three specific types of sports were associated with the largest reductions in risk, much of the media commentary2 was consumed with aetiological explanations3 5–7 of the beneficial associations that participation in certain sports conferred. On the other hand, an alternative explanation is that our findings of lower mortality did not reflect the health attributes of the examined sports but, instead, they were related to socioeconomic characteristics of the participants of certain sports. For example, as football is perceived …
Evaluation of IGHV Ultra-Deep Sequences for Activation-Induced Deaminase Characteristics in CLL Cells after T Cell Stimulation
Authors: Charles C. Chu, Piers E.M. Patten, Thomas MacCarthy, Xiao-Jie Yan, Jacqueline C. Barrientos, Jonathan E. Kolitz, Steven L. Allen, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2013)